


What is CanAssist Breast?


CanAssist Breast (CAB) is a prognostic test developed by OncoStem for eligible* breast cancer patients. CAB is performed on patient's tumor sample removed during surgery and provides information about risk of breast cancer recurrence beyond what current conventional methods can offer. CAB determines whether a patient has "low- or high-risk" of breast cancer recurrence, which helps oncologists in deciding use of chemotherapy and/or additional therapies.



How CAB works?



What makes CAB unique?



***Eligibility Criteria for CanAssist Breast:** Stage I & II breast cancer patients with invasive breast carcinoma who have hormone-positive and HER2-negative tumours with 0-3 positive lymph nodes.

Turn around time:
8 working days

Download CanAssist Breast publications:



Therapeutic Advances
in Medical Oncology
(2025)
Vol 17



Cureus
(2024)
Vol 16



Cancer Medicine
(2023)
Vol 12



Breast Cancer
Research
(2023)
Vol 25



Breast Cancer
Research
Treatment (2022)
Vol 196